Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
37.01 K
Value Traded
9.38 K
Short % Float
-
Days to Cover
1.0
+8.74%Week
+7.26%1 Month
-10.53%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
287.28 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
28.15 M
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VCRE Catalyst Timeline
Dated clinical, regulatory and corporate events for Vicore Pharma Holding AB American Depositary Shares
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vicore Pharma Holding AB American Depositary Shares
8Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 1
TBD
T3Enrollment Update
Subscribe to view catalyst details
Event history 1
▼Equity OfferingCorporate
Vicore shares and votes increased via exercise of 117,737 share awards (118,916 shares)
Past FDA Catalysts and PDUFA Decisions
How VCRE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 35%
Micro Cap(rank 231 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buloxibutid Small moleculeNCT06588686 | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | ACTIVE NOT_RECRUITING | 378 | Jun 1, 2027 | ||||||
| C21 Small moleculeCompletedNCT04452435 | COVID-19 | Phase 3 | COMPLETED | 478 | Oct 13, 2020 | ||||||
| C21 Small moleculeCompletedNCT04533022 | Idiopathic Pulmonary Fibrosis | Phase 2 | COMPLETED | 52 | Mar 30, 2024 | ||||||
| C21 Small moleculeCompletedNCT05277922 | Study Vasodilatory Effects of C21 | Phase 1 | COMPLETED | 5 | May 18, 2022 | ||||||
| C21 Small moleculeCompletedNCT05831644 | Type2diabetes | Phase 1 | COMPLETED | 11 | Jun 20, 2023 | ||||||
| Drug Drug Interaction Small moleculeCompletedNCT05830799 | Drug Interaction | Phase 1 | COMPLETED | 19 | May 11, 2023 | ||||||
| C106 Small moleculeCompletedNCT05427253 | Safety Issues | Phase 1 | COMPLETED | 80 | Jun 22, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every VCRE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VCRE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VCRE for Q2 2026. | ||||
VCRE Institutional Ownership Trends
VCRE Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
1.0K
Shares Sold Short
-75.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
27.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VCRE ranks across every disease it competes in
Competitive Position is a premium feature
See how VCRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVCRE News
-VCRE
Oct 13, 2026Vicore Pharma to Participate in the Chardan Healthcare Conference
Vicore Pharma Holding AB announced its participation in the Chardan Healthcare Conference, scheduled for October 20, 2026. The event will feature a panel discussion on idiopathic pulmonary fibrosis and chronic respiratory diseases. Vicore is advancing its lead program, buloxibutid, which is currently in a Phase 2b trial.
Read more →-VCRE
Sep 30, 2026Increase in Number of Shares and Votes in Vicore Pharma
Vicore Pharma Holding AB has announced an increase in the number of shares and votes following the exercise of warrants related to its incentive programs. A total of 118,916 new shares were issued, raising the share capital by approximately 59,458 SEK. The total number of registered shares now stands at 281,644,509. Vicore Pharma is focused on developing new drug candidates for respiratory and fibrotic diseases.
Read more →-VCRE
Sep 17, 2026Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
Vicore Pharma will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. Key executives, including the CEO, CFO, and CMO, will participate in the event. The company focuses on developing angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases, with its lead drug currently in a Phase 2b trial.
Read more →-VCRE
Sep 1, 2026Vicore Pharma to Participate in Upcoming Healthcare Conferences
Vicore Pharma Holding AB announced its participation in two upcoming healthcare conferences. CEO Ahmed Mousa will represent the company at the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference. The company is focused on developing angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases, with its lead program currently in a Phase 2b trial.
Read more →-VCRE
Jul 6, 2026Citi Appointed as Depositary Bank for Vicore Pharma Holding AB’s ADR Program
Citi has been appointed as the depositary bank for Vicore Pharma Holding AB's American Depositary Receipt (ADR) program. This appointment is expected to facilitate the trading of ADRs for Vicore Pharma, enhancing its visibility in the U.S. market. The move aims to attract more investors and improve liquidity for the company's shares.
Read more →About Vicore Pharma Holding AB American Depositary Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next VCRE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime